In the field of Big Data, after genomics and proteomics, appeared metabolomics and lipidomics, i.e. the study of all the molecules linked to the metabolism and lipid composition of organs and plasma. Numerous studies have shown that this molecular signature changes during cardiometabolic diseases and that it can be used as a biomarker or therapeutic target. An example is the link between serum lipid profile and the risk of progression of atherosclerosis.

Many factors modify this metabolic and lipid signature such as sex, body mass index, age, lifestyle…which makes its study difficult. IHU-ICAN has developed innovative holistic approaches targeting a broad spectrum of molecules, from very polar metabolites to very apolar lipids thanks to the combination of chromatography (liquid (LC) or gaseous (GC)) coupled with spectrometry technology mass (HRMS, MS/MS or MS). For the integration and analysis of the data, various tools have been developed, including a dedicated multi-omics integration method allowing the discrimination of metabolic phenotypes, called DIABLO, has been implemented.

ICAN Omics lipidomics

In close collaboration with researchers and clinicians from the ICAN community, the lipidomics platform, created in 2010, is particularly committed to identifying new lipid biomarkers in the field of cardiometabolism and nutrition with the aim of improving the prevention and refine patient stratification for more personalized treatment.


ICAN Omics metabolomics

The purpose of the metabolomics platform is to develop and provide tools for high-throughput profiling and/or quantification of all the molecules belonging to the metabolome for mechanistic purposes or the search for new biomarkers.